

## MyAir closes A Series funding with Istituti Clinici Scientifici Maugeri SpA SB

*Maugeri and MyAir strategic partners for the development of Airgo, first CE marked wireless medical device for respiratory monitoring, used for Covid-19 patients in USA and Italy*

Milan, 21 December 2020 - MyAir, Inc., a medtech company based in Boston and Milan specialized in respiratory disease diagnostics, completed the A Series funding round with the entry of the ICS Maugeri, **for 1 million Euros**, in cash and clinical services, aimed at financing the development of new platform functionalities Airgo for breathing monitoring, in continuity with the results already obtained by Maugeri for their patients with Covid or sleep disorders. Maugeri becomes a co-investor with the fund HTH whose entry into the capital of MyAir was announced about a month ago.

The platform is based on Airgo, the first wireless, **non-invasive, easy-to-use medical recorder developed for 24/7, real time respiratory parameter monitoring**, with clinical quality and accuracy, both in the hospital and at home. Airgo allows doctors to **review vital signs and respiratory trends at a distance**, and promptly intervene in the event of respiratory failure crises.

**The collaboration between Maugeri and MyAir** has been underway for some time, resulting in multiple clinical trials on over 150 patients, targeting the use of Airgo as an automated screening tool for sleep apnoea. The trials revealed the ease of use and clinical quality and validity of the respiratory parameters developed by Airgo. This led the doctors of ICS Maugeri to apply it towards **24/7 monitoring and rehabilitation of Covid patients**.

With the contribution of **Vodafone Italia**, which provided connectivity and devices, Maugeri monitored Covid patients in hospital by recording more than **300 days of respiratory data**, while **limiting the direct exposure** of staff to the Covid virus.

In addition to the multi-site extension of Covid patient trials, the collaboration between Maugeri and MyAir covers the **use of Airgo for monitoring, diagnostics and patient care** with other critical respiratory diseases such as **COPD, heart failure, ALS, muscular dystrophy**. The work of the MyAir team in collaboration with the specialists of ICS Maugeri will guarantee a constant improvement of the Airgo platform.

Developed and self-financed by the founders of MyAir, **Airgo** obtained **CE certification as a Class II (a) medical device** and has been used successfully on over 1,000 patients at world renowned clinical centers specialized in telemedicine - in the USA (over **800 patients at Harvard Mass General Hospital** and more than **50 patients at the Minnesota Sleep Clinic**) and in Italy (over **250 patients at ICS Maugeri Veruno** and at the **S. Croce and Carle Hospital in Cuneo**).

Thanks to the unique combination of **ergonomics, autonomy, 24/7 telemetry, AI assisted automated analytics and diagnostics** provided by the **Airgo Console** during the Covid-19

emergency US and Italian doctors immediately recognized the usefulness of the Airgo device to provide information and data useful for promptly determining the therapeutic path.

Commenting on the closing of the funding round, **David Kuller, founder of MyAir states:** "We are thrilled with the strategic partnership with Maugeri: their in-depth knowledge of respiratory medicine, and their network of doctors, researchers and health facilities, united with our ability to innovate will help expand and refine the use of Airgo in the rehabilitation of patients suffering from respiratory diseases, which require personalized treatments on site and remotely."

"Innovating in the interest of the patient - says **Mario Melazzini, CEO of ICS Maugeri Spa SB** - is what has characterized the history of our institutes. Telemedicine is the great challenge that we have undertaken for some time, and this has enabled our health professionals to obtain important results in dealing with the Covid-19 emergency and the rehabilitation of patients through innovative paths. The partnership with MyAir for development of the Airgo platform was important because it is consistent with the innovation path undertaken and we are particularly satisfied with the results obtained because they allow better quality of patient care."

-----  
**MyAir**

MyAir Inc. was founded in 2015 to continue the development of Airgo, a technology platform invented by David Kuller for the 2013 HHS/EPA MyAir MyHealth competition - this challenge sought innovative solutions for respiratory monitoring. Airgo won the contest and \$150k and has since been self-financed by its founders. During this period MyAir has evolved Airgo through 5 generations of platform technology, each validated clinically in several of the finest hospitals in America and Italy. MyAir now has offices in Boston and Milan and a vast network of KOLs actively formulating Airgo based solutions to a wide variety of cardio/pulmonary/sleep diagnostics and cure. The MyAir mission, together with investors, is to revolutionize healthcare using remotely gathered natural respiratory biomarkers 24/7.

<https://www.myairgo.com/>

**ICS Maugeri**

ICS Maugeri SpA SB is a leader in Italy in rehabilitation medicine, with about 2,400 accredited beds, of which about 2,000 are dedicated to rehabilitation, in 17 institutes in 6 Italian regions as well as 3 outpatient clinics and an environmental research institute. It inherits the tradition of the Salvatore Maugeri Foundation, operating since 1965 and since 1969 a Scientific Research and Care Institute (IRCCS), a recognition that the company retains.